Key clinical point: The ratio of apolipoproteins B and A1 (apo B/A1) was an independent prognostic factor in patients with metastatic renal cell carcinoma (RCC).
Major finding: The preoperative apo B/A1 ratio was independently prognostic for progression-free survival and overall survival, with hazard ratios of 3.131 and 2.173, respectively (P less than .001 for both).
Study details: A retrospective, single-center study including 287 patients with metastatic RCC who underwent cytoreductive nephrectomy.
Disclosures: Beijing Natural Science Foundation supported the study. Dr. Zhang and coauthors had no disclosed conflicts of interest.
Zhang F et al. Urol Oncol. 2018 Nov 30. doi: 10.1016/j.urolonc.2018.11.010.
This Week's Must Reads
Must Reads in Renal Cell Carcinoma
First-line avelumab/axitinib for RCC benefits wide range of patients, Choueiri TK et al. GUCS 2019, Abstract 544.
One-fourth of placebo arm experience adverse events in RCC trials, Chacón M et al. JAMA Network Open. 2018 Dec 7. doi: 10.1001/jamanetworkopen.2018.5617
Strong link found between RCC and melanoma, Kim KB et al. Cancer Epidemiol. 2018 Oct 19;57:80-4